Global Hemophilia Market Size, Share, Trends, Growth and Forecast 2032
Hemophilia Market - By Disease Type (Hemophilia A, Hemophilia B, and Others), By Therapy (Gene Therapy, Replacement Therapy, and Others), By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, and Others), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024-2032
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 13.01 Billion | USD 23.08 Billion | 6.58% | 2023 |
Table Of Content
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Hemophilia Market, 2015–2025 (USD Billion)
- 2.2. Hemophilia Market: Snapshot
- Chapter 3. Global Hemophilia Market– Industry Analysis
- 3.1. Hemophilia Market: Market Dynamics
- 3.2. Market Drivers
- 3.2.1. Focus on new drug development along with favorable government pulicies for curbing the disease is likely to prompt the expansion of hemophilia market over the forecast timespan.
- 3.2.2. Rise in the awareness about rare disease such as hemophilia and growing efforts made by both private & public healthcare research organizations to produce drugs for effectively treating the disorder will impel the business growth.
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Attractiveness Analysis
- 3.4.1. Market attractiveness analysis By Disease Type
- 3.4.2. Market attractiveness analysis By Therapy
- 3.4.3. Market attractiveness analysis By Product Type
- Chapter 4. Global Hemophilia Market– Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global Hemophilia Market: company market share, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New Product launches
- 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4. Research and development and Regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Hemophilia Market– Disease Type Analysis
- 5.1. Global Hemophilia Market overview: By Disease Type
- 5.1.1. Global Hemophilia Market share, By Disease Type , 2019 and 2025
- 5.2. Hemophilia A
- 5.2.1. Global Hemophilia Market By Hemophilia A , 2015–2025 (USD Billion)
- 5.3. Hemophilia B
- 5.3.1. Global Hemophilia Market By Hemophilia B, 2015–2025 (USD Billion)
- 5.4. Others
- 5.4.1. Global Hemophilia Market By Others , 2015–2025 (USD Billion)
- 5.1. Global Hemophilia Market overview: By Disease Type
- Chapter 6. Global Hemophilia Market– Therapy Analysis
- 6.1. Global Hemophilia Market overview: By Therapy
- 6.1.1. Global Hemophilia Market share, By Therapy , 2019 and 2025
- 6.2. Gene Therapy
- 6.2.1. Global Hemophilia Market By Gene Therapy, 2015–2025 (USD Billion)
- 6.3. Replacement Therapy
- 6.3.1. Global Hemophilia Market By Replacement Therapy, 2015–2025 (USD Billion)
- 6.4. Others
- 6.4.1.1. Global Hemophilia Market By Others, 2015–2025 (USD Billion)
- 6.1. Global Hemophilia Market overview: By Therapy
- Chapter 7. Global Hemophilia Market– Product Type Analysis
- 7.1. Global Hemophilia Market overview: By Product Type
- 7.1.1. Global Hemophilia Market share, By Product Type , 2019 and 2025
- 7.2. Plasma-Derived Coagulation Factor Concentrates
- 7.2.1. Global Hemophilia Market By Plasma-Derived Coagulation Factor Concentrates, 2015–2025 (USD Billion)
- 7.3. Recombinant Coagulation Factor Concentrates
- 7.3.1. Global Hemophilia Market By Recombinant Coagulation Factor Concentrates, 2015–2025 (USD Billion)
- 7.4. Others
- 7.4.1.1. Global Hemophilia Market By Others, 2015–2025 (USD Billion)
- 7.1. Global Hemophilia Market overview: By Product Type
- Chapter 8. Company Profiles
- 8.1. BioMarin Pharmaceutical, Inc.
- 8.1.1. Overview
- 8.1.2. Financials
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategy
- 8.1.5. Recent Developments
- 8.2. Bayer AG
- 8.2.1. Overview
- 8.2.2. Financials
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategy
- 8.2.5. Recent Developments
- 8.3. Kedrion
- 8.3.1. Overview
- 8.3.2. Financials
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategy
- 8.3.5. Recent Developments
- 8.4. CSL Behring
- 8.4.1. Overview
- 8.4.2. Financials
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategy
- 8.4.5. Recent Developments
- 8.5. Pfizer, Inc.
- 8.5.1. Overview
- 8.5.2. Financials
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategy
- 8.5.5. Recent Development
- 8.6. Novo Nordisk
- 8.6.1. Overview
- 8.6.2. Financials
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategy
- 8.6.5. Recent Development
- 8.7. Sanofi (Genzyme Corporation)
- 8.7.1. Overview
- 8.7.2. Financials
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategy
- 8.7.5. Recent Development
- 8.8. Roche (Chugai Pharmaceutical Co.)
- 8.8.1. Overview
- 8.8.2. Financials
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategy
- 8.8.5. Recent Development
- 8.9. Takeda Pharmaceutical (Shire Plc.)
- 8.9.1. Overview
- 8.9.2. Financials
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategy
- 8.9.5. Recent Development
- 8.1. BioMarin Pharmaceutical, Inc.
Table Of Figures
List of Figures
1. Market research process
2. Market research methodology
3. Global Hemophilia Market, 2015–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Global Hemophilia Market attractiveness, By Disease Type
6. Global Hemophilia Market attractiveness, By Therapy
7. Global Hemophilia Market attractiveness, By Product Type
8. Global Hemophilia Market Share by Disease Type ,2019 and 2025 (USD Billion)
9. Global Hemophilia Market by Hemophilia A ,2015–2025 (USD Billion)
10. Global Hemophilia Market by Hemophilia B ,2015–2025 (USD Billion)
11. Global Hemophilia Market by Others ,2015–2025 (USD Billion)
12. Global Hemophilia Market Share by Therapy ,2019 and 2025 (USD Billion)
13. Global Hemophilia Market by Gene Therapy,2015–2025 (USD Billion)
14. Global Hemophilia Market by Replacement Therapy,2015–2025 (USD Billion)
15. Global Hemophilia Market by Others,2015–2025 (USD Billion)
16. Global Hemophilia Market Share by Product Type ,2019 and 2025 (USD Billion)
17. Global Hemophilia Market by Plasma-Derived Coagulation Factor Concentrates,2015–2025 (USD Billion)
18. Global Hemophilia Market by Recombinant Coagulation Factor Concentrates,2015–2025 (USD Billion)
19. Global Hemophilia Market by Others,2015–2025 (USD Billion)
20. Global Hemophilia Market share, by Region, 2019 and 2025
21. North America Hemophilia Market, 2015–2025 (USD Billion)
22. Europe Hemophilia Market, 2015–2025 (USD Billion)
23. Asia Pacific Hemophilia Market, 2015–2025 (USD Billion)
24. Latin America Hemophilia Market, 2015–2025 (USD Billion)
25. The Middle East and Africa Hemophilia Market, 2015–2025 (USD Billion)
Table Of Tables
List of Tables
1. Global Hemophilia Market: snapshot
2. Drivers of the Hemophilia Market: impact analysis
3. North America Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
4. North America Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
5. North America Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
6. The U.S. Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
7. The U.S. Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
8. The U.S. Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
9. Rest of North America Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
10. Rest of North America Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
11. Rest of North America Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
12. Europe Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
13. Europe Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
14. Europe Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
15. UK Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
16. UK Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
17. UK Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
18. France Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
19. France Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
20. France Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
21. Germany Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
22. Germany Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
23. Germany Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
24. Rest of Europe Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
25. Rest of Europe Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
26. Rest of Europe Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
27. Asia Pacific Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
28. Asia Pacific Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
29. Asia Pacific Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
30. China Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
31. China Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
32. China Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
33. Japan Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
34. Japan Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
35. Japan Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
36. India Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
37. India Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
38. India Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
39. Rest of Asia Pacific Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
40. Rest of Asia Pacific Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
41. Rest of Asia Pacific Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
42. Latin America Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
43. Latin America Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
44. Latin America Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
45. Brazil Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
46. Brazil Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
47. Brazil Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
48. Rest of Latin America Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
49. Rest of Latin America Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
50. Rest of America Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
51. The Middle East and Africa Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
52. The Middle East and Africa Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
53. The Middle East and Africa Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
54. Saudi Arabia Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
55. Saudi Arabia Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
56. Saudi Arabia Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
57. South Africa Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
58. South Africa Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
59. South Africa Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
60. Rest of the Middle East & Africa Hemophilia Market revenue, By Disease Type , 2015–2025 (USD Billion)
61. Rest of the Middle East & Africa Hemophilia Market revenue, By Therapy , 2015–2025 (USD Billion)
62. Rest of the Middle East & Africa Hemophilia Market revenue, By Product Type , 2015–2025 (USD Billion)
Methodology
FrequentlyAsked Questions
Hemophilia is a genetic disorder that affects blood clotting. It causes excessive bleeding from minor injuries
The global Hemophilia market is expected to be driven by the rising diagnosis rates, advancements in clotting factor therapies, and gene therapy development. Improved treatment accessibility supports expansion..
According to study, the global Hemophilia market size was worth around USD 13.01 Billion in 2023 and is predicted to grow to around USD 23.08 Billion By 2032.
The global Hemophilia market is expected to grow at a Compound Annual Growth Rate (CAGR) of around CAGR 6.58% during the forecast period from 2024-2032.
The global Hemophilia industry is projected to be challenged by Challenges include high treatment costs, limited access in developing regions, and lifelong therapy dependence.
The Opportunities include gene therapy advancements, extended half-life treatments, improved diagnosis, and orphan drug incentives will offer significant growth opportunities in the Hemophilia market.
Long-acting factor therapies; gene therapy breakthroughs; personalized prophylaxis and home-based treatment models are the emerging trends and innovations impacting the Hemophilia market.
The global Hemophilia market is expected to be led by North America during the forecast period.
Some of the prominent players operating in the global Hemophilia market are; Novo Nordisk; CSL Behring; BioMarin Pharmaceutical, Inc.; Roche (Chugai Pharmaceutical Co.); Pfizer, Inc.; Bayer AG; Sanofi (Genzyme Corporation);Kedrion; and Takeda Pharmaceutical (Shire Plc.). and others.
The report explores crucial aspects of the Hemophilia market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients
